MMI S.r.l. is an Italian company that specializes in the manufacture and development of advanced micro instruments designed for surgical interventions. Founded in 2015 and based in Calci, Italy, MMI focuses on creating wristed micro instruments and their associated fabrication processes. The company also offers a proprietary robotic platform that enhances the capabilities of these instruments, facilitating complex reconstruction procedures following traumatic injuries and tumor removals in areas such as the breast, head, and bones. MMI aims to support surgeons globally by providing innovative tools that improve surgical outcomes while also reducing costs for patients and healthcare systems.
InSilico Medicine, Inc. is an artificial intelligence company focused on drug discovery, biomarker development, and aging research. Founded in 2014 and headquartered in Baltimore, Maryland, the company employs advanced AI technologies, including deep learning and generative adversarial networks, to create novel molecular structures for diseases with known and unknown targets. Its comprehensive platform covers all stages of drug development, from discovery to clinical trials. Key initiatives include Pharma.AI, which offers machine learning services to various industries, and Young.AI, which predicts biological age. InSilico Medicine also engages in internal drug discovery programs targeting conditions such as cancer, Parkinson's Disease, and age-related disorders. Additionally, the company has partnered with Life Extension to develop nutraceutical products using its bioinformatics and deep learning techniques. Through its innovative solutions, InSilico Medicine aims to enhance personalized healthcare and mitigate the effects of aging.
Epic Sciences, Inc. is a diagnostics company based in San Diego, California, focused on improving cancer management through innovative testing methods. The company specializes in developing highly sensitive tests to identify and characterize circulating tumor cells (CTCs) from minimally invasive blood samples. Its advanced platform can profile single-cell phenotypes and genotypes, assessing various characteristics such as biomarker expression levels and morphologic traits. Epic Sciences also offers the Oncotype DX AR-V7 Nucleus Detect test for patients with metastatic castration-resistant prostate cancer, along with biopharmaceutical solutions. The company collaborates with biotechnology and pharmaceutical partners, major cancer centers, and research institutions, including the National Cancer Institute and the National Institutes of Health, to enhance personalized medicine and provide real-time biopsy material for cancer treatment guidance. Founded in 2008, Epic Sciences is committed to facilitating quick and effective cancer diagnostics.
Acutus Medical, Inc. is an arrhythmia management company that specializes in developing medical technologies for diagnosing and treating complex cardiac arrhythmias. Founded in 2011 and based in Carlsbad, California, the company designs, manufactures, and markets a comprehensive range of tools for catheter-based ablation procedures. Its product offerings include advanced imaging and mapping systems, such as the AcQMap console and workstation, along with diagnostic catheters and therapeutic devices like ablation catheters and robotic navigation systems. Acutus Medical's innovative platform enables electrophysiologists to visualize the heart's activation patterns, facilitating more effective treatment of arrhythmias. The company collaborates with medical scientists and engineers in the U.S. and Europe to enhance its product development and provides solutions to hospitals and electrophysiologists globally.
Operator of a biotechnology company intended for pioneering the development of genetic medicines for treating intractable diseases. The company specializes in developing genetic drugs by simultaneously engineering (Adeno-associated viruses) AAV capsids that bind to the human Transferrin Receptor 1 (TfR1) to enable intravenous delivery of therapeutics that use receptor-mediated transcytosis across the blood brain barrier allowing broad penetration of the central nervous system, and payloads to overcome limitations in cellular access, gene expression, pre-existing immunity and manufacturability, thereby enabling patients to treat debilitating diseases with limited options.
Somatus is a healthcare company that partners with health plans, health systems, and nephrology, and primary care groups. It provides integrated care for patients with or at risk of developing kidney disease. Somatus' is vertically integrated clinical services and technology delay or prevent disease progression, improve quality and care coordination, and increase the use of home dialysis modalities and rates of kidney transplantation.
The company is headquartered in McLean, Virginia, and founded by a team of world-class healthcare operators, successful entrepreneurs, and leading clinicians treating kidney disease.
ConcertoCare provides healthcare services primarily to dual-eligible patients enrolled in Medicare and Medicaid, as well as those with complex medical needs. The company focuses on addressing critical vulnerabilities faced by these patients and health plans by offering personalized primary care, chronic condition management, and support for transitions between various care settings. Additionally, ConcertoCare delivers medical, social, and logistical assistance to enhance patient outcomes. Founded in 2004 and based in Aliso Viejo, California, the company operates care centers in locations including Renton, Washington, and several cities in Michigan. The name Concerto reflects its holistic approach to healthcare, emphasizing collaboration among patients, providers, and health plans to ensure coordinated care that respects the dignity and health of each individual.
Hyperfine Research Inc. specializes in developing portable magnetic resonance imaging (MRI) scanners, aimed at making medical imaging more accessible. Founded in 2014 and based in Guilford, Connecticut, the company focuses on general anatomical brain imaging and addresses various medical conditions, including headaches, strokes, non-specific muscle weakness, encephalopathy, spinal cord compressions, diabetic foot disease, and musculoskeletal trauma. Within a year of its establishment, Hyperfine successfully produced its first images, and it has since improved the quality and functionality of its imaging technology. The company’s mission is to democratize healthcare by ensuring that medical imaging is available to people worldwide.
DeepSight Technology is a health technology company focused on enhancing diagnostic medical imaging through its innovative platform. Utilizing proprietary sensing technology, DeepSight combines patented hardware, software, and artificial intelligence to significantly improve image quality and extend the depth penetration of medical diagnostic ultrasounds. This advancement not only makes medical imaging safer, faster, and more affordable but also increases accessibility for healthcare providers. By offering cutting-edge sensor technology, DeepSight aims to broaden the capabilities of diagnostic ultrasounds, ultimately benefiting public health and well-being.
Sema4 is a patient-centered predictive health company dedicated to advancing the diagnosis, treatment, and prevention of disease. With their innovative Sema4 Health Intelligence Platform, they’re using advanced network analysis to build better models of human health and deliver personalized insights for patients.
Frontier Medicines Corporation is a pre-clinical stage biopharmaceutical company based in South San Francisco, California, founded in 2018. The company specializes in discovering and developing medicines that target cancer-causing proteins through its innovative chemoproteomics platform. This platform utilizes advanced computational techniques and machine learning to identify new binding pockets on proteins, thereby facilitating the discovery and development of small-molecule drugs. By enhancing the drug development process, Frontier Medicines aims to deliver breakthrough therapies that can significantly change the treatment landscape for debilitating diseases.
Operator of cardiovascular care delivery network intended to improve the quality and value of disease care. The company's platform facilitates building symbiotic relationships with health plans and primary care partners, along with an array of other capabilities including implementation of quality and process improvement efforts and technology-enabled care delivery among others, enabling clients to transition easily to value-based care.
Adela is focused on the detection of cancer and other high-morbidity, high-mortality conditions through a routine blood test.
CareMax is a technology-enabled care platform providing value-based care and chronic disease management to seniors. CarMax operates medical centers that offer a comprehensive suite of healthcare and social services, and a proprietary software and services platform that provides data, analytics, and rules-based decision tools/workflows for physicians across the United States.
Adaptive Phage Therapeutics, Inc. specializes in developing therapeutic solutions to combat the increasing threat of multi-drug resistant (MDR) bacteria. Founded in 2016 and based in Gaithersburg, Maryland, the company utilizes a unique resource known as PhageBank, which is an extensive and dynamic collection of bacteriophages—viruses that specifically target and attack harmful bacteria. Through a rapid system that matches these phages to individual patient bacterial infections, Adaptive Phage Therapeutics aims to enhance treatment options for patients suffering from MDR infections. Their innovative approach enables medical researchers to create tailored therapies that effectively detect and eliminate resistant bacterial strains.
Cohere Health, Inc. is a software-as-a-service company based in Boston, Massachusetts, that focuses on enhancing the healthcare experience for patients, providers, and health plans. Incorporated in 2019, the company aims to improve the quality of care while reducing overall costs and increasing transparency throughout the patient care journey. Cohere Health specializes in intelligent prior authorization services, which are tailored to meet the specific needs of different health plans. By leveraging artificial intelligence, machine learning, and real-time analytics, the company automates the prior authorization process and facilitates collaboration between physicians and health plans. This approach not only streamlines the utilization management service but also promotes quality care across the entire patient journey.
Crossover Health, Inc. is a healthcare provider focused on delivering comprehensive workplace healthcare services tailored for employers and their employees. Founded in 2010 and headquartered in Aliso Viejo, California, the company operates health centers in various locations, including Silicon Valley. Crossover Health offers a wide range of services, such as primary care, urgent care, preventive care, chronic disease management, health education, physical therapy, and remote care, among others. By integrating various health and wellness benefits with technology-enabled services, Crossover Health aims to enhance access to care and reduce healthcare costs for companies. The firm collaborates closely with client partners to customize health services based on health analytics, fostering a culture of health ownership among employees while improving both the quality of care and the overall employee experience.
Spectrawave, Inc. is a medical device company based in Waltham, Massachusetts, founded in 2017. The company specializes in developing and manufacturing optical diagnostic and therapeutic devices aimed at enhancing the diagnosis and treatment of cardiovascular diseases. One of its key innovations is a spectroscopy catheter that integrates advanced imaging technologies to improve outcomes for patients with coronary artery disease (CAD). This cutting-edge imaging system provides interventional cardiologists with crucial optical and computational insights, enabling them to identify patients and plaque formations that may pose risks for future coronary complications. Through its focus on photonics, Spectrawave aims to optimize stent interventions and improve overall patient care in the field of cardiovascular medicine.
MIVI Neuroscience, Inc. is a medical device company based in Eden Prairie, Minnesota, specializing in clinical solutions for neurointerventional procedures. Founded in 2013, the company offers an innovative portfolio that includes products such as high flow tubing, various guide and diagnostic catheters, and aspiration pumps. MIVI's devices are designed to enhance patient outcomes by improving the safety and efficacy of treatments for ischemic stroke, facilitating the removal of obstructions and restoring blood flow. By focusing on reducing complications and procedure times, MIVI aims to expand treatment options for a broader range of patients, ultimately advancing the field of neurointervention.
FogPharma is a healthcare company founded in 2015 and headquartered in Gloucester, Massachusetts. The firm is dedicated to the pharmaceutical sector, with a primary focus on developing innovative treatments for cancer. It operates with the support of a diverse group of private and institutional investors, fostering collaboration among its founders, employees, and advisors. FogPharma aims to create a new class of medicines designed to extend and enhance the lives of cancer patients. The company's commitment to its mission drives its efforts to pioneer effective solutions in cancer treatment.
Cystetic Medicines
Funding Round in 2020
Cystetic Medicines develops a treatment that potentially could help people with cystic fibrosis (CF), regardless of genetic mutation.
Bridge Medicines LLC offers drug discovery services. It focuses on developing technologies in academic institutions from human proof-of-concept to clinical development. The company develops inhibitors of ENL-YEATS for the treatment of acute leukemias, such as acute myelogenous leukemia and a series of orally active small molecule inhibitors of activated factor XII for the treatment of hereditary angioedema and other inflammatory disorders. Bridge Medicines LLC was founded in 2016 and is based in New York, New York.
Curation Health, LLC offers a clinical decision support platform designed to facilitate the transition from fee-for-service to value-based care. Founded in 2018 and based in Annapolis, Maryland, the company provides a point-of-care solution that integrates with electronic health records to deliver actionable risk adjustment insights. This platform captures accurate clinical data before and after patient visits, ensuring comprehensive provider documentation. Curation Health's services enhance performance for various healthcare programs, including Medicare Advantage, MSSP, Medicaid risk programs, and quality initiatives based on standard measures. By leveraging clinical and quality rules, the platform aims to improve documentation processes and the overall value of patient care.
Olema Oncology is a clinical-stage biopharmaceutical company dedicated to developing targeted therapies for women's cancers, particularly estrogen receptor (ER)-positive breast cancer. The company's lead candidate, OP-1250, is an ER antagonist and selective ER degrader currently undergoing Phase 1/2 clinical trials for the treatment of metastatic or locally advanced, ER-positive, and human epidermal growth factor receptor 2-negative breast cancer. Olema's research focuses on utilizing its expertise in endocrine-driven cancers and the molecular mechanisms of the ER to create more effective treatments that aim to improve patient outcomes. In addition to OP-1250, Olema is advancing another drug candidate, OP-3136, further enriching its pipeline. Established in 2006 and headquartered in San Francisco, California, Olema is committed to transforming the standard of care for women facing these challenging diagnoses.
Ready Responders, Inc. focuses on enhancing community health by providing immediate medical care and support for various health needs. Founded in 2016 and headquartered in New Orleans, Louisiana, the company offers services such as 911 quick responses, telehealth consultations, and patient access to emergency medical professionals. Their responders visit patients at home to address physical, mental, and social health needs, utilizing technology to connect with advanced medical providers. Ready Responders also facilitates connections to external resources for ongoing support and aims to improve patient experiences while reducing overall care costs. The company operates in multiple locations across Louisiana, Nevada, New York City, and the National Capital Region, and is in-network with many major insurance providers.
Reprieve Cardiovascular, Inc., a medical device company, develops and manufactures a medical fluid management device for congestive heart failure. It offers Reprieve technology, a fluid management therapy solution providing clinicians with the ability to precisely control a patient’s fluid volume for acute decompensated heart failure (ADHF) patients. The company was founded in 2018 and is based in Milford, Massachusetts. Reprieve Cardiovascular, Inc. operates as a subsidiary of CardioRenal Systems, Inc.
Sema4 is a patient-centered predictive health company dedicated to advancing the diagnosis, treatment, and prevention of disease. With their innovative Sema4 Health Intelligence Platform, they’re using advanced network analysis to build better models of human health and deliver personalized insights for patients.
Private Equity Round in 2020
QMES, LLC is a privately held company specializing in the distribution of medical equipment and supplies. It serves hospitals, rehabilitation centers, skilled nursing facilities, and home patients across Pennsylvania, New Jersey, New York, Maryland, and Delaware. Founded in 2012 and based in Phoenixville, Pennsylvania, QMES provides a diverse range of products, including those for sleep and respiratory therapy, mobility aids, wound care, non-invasive ventilation, and nutritional support. Additionally, the company offers services such as respiratory therapy, wound care, nursing, and dietary consultations. To enhance customer convenience, QMES also provides online bill payment services, allowing users to manage and pay for their medical equipment expenses. The company is committed to addressing the unique challenges faced by patients, healthcare providers, and facilities during the transition from hospital to home care.
Somatus is a healthcare company that partners with health plans, health systems, and nephrology, and primary care groups. It provides integrated care for patients with or at risk of developing kidney disease. Somatus' is vertically integrated clinical services and technology delay or prevent disease progression, improve quality and care coordination, and increase the use of home dialysis modalities and rates of kidney transplantation.
The company is headquartered in McLean, Virginia, and founded by a team of world-class healthcare operators, successful entrepreneurs, and leading clinicians treating kidney disease.
Meditrina, Inc., founded in 2016 and based in San Jose, California, specializes in developing innovative medical devices for tissue removal solutions related to intrauterine pathology. The company provides the Aveta system, designed for healthcare professionals to facilitate hysteroscopic diagnostic and therapeutic procedures, including the removal of polyps and fibroids. In addition to its tissue removal products, Meditrina is also focused on creating fully disposable endoscopes and a comprehensive visualization system intended for use in both office and clinical settings, catering to various medical procedures.
ARTMS Products Inc. is a Vancouver-based company that specializes in manufacturing diagnostic imaging systems for the production and separation of medical isotopes. Founded in 2013, the company has developed the QUANTM Irradiation System, which facilitates decentralized and local production of critical isotopes such as gallium-68, zirconium-89, technetium-99m, and copper-64. ARTMS's primary offering, QUANTM99, is a system that combines hardware and consumables for the effective production of technetium-99m using medical cyclotrons. This innovative approach aims to enhance the accessibility and cost-effectiveness of medical isotopes, improving diagnostic imaging services.
CorVent Medical
Seed Round in 2020
CorVent Medical is developing smart, versatile, lifesaving ventilators for critical care. The company's first product, the CorVent™ Single-Use Ventilator, was designed in partnership with Design Catapult, an industrial design firm recognized for their rapid ideation of medical and commercial products. The ventilator is currently pending Emergency Use Authorization (EUA) issued by the U.S. Food and Drug Administration (FDA) for ventilators, tubing connectors and accessories, which authorizes its use for the duration of the U.S. Health and Human Services COVID-19 public health emergency declaration.
LetsGetChecked is an at-home health testing platform that connects customers to regulated laboratory testing to better manage and control one's individual health. LetsGetChecked is making healthcare and diagnostics open and patient-led, empowering people to use technology in a simple yet powerful way. This offers consumers greater control over their individual health. LetsGetChecked is headquartered in New York, NY, with tests covering general wellness, sexual health, women's health and men's health, and is available nationwide, as well as in Canada and Europe.
Ready Responders, Inc. focuses on enhancing community health by providing immediate medical care and support for various health needs. Founded in 2016 and headquartered in New Orleans, Louisiana, the company offers services such as 911 quick responses, telehealth consultations, and patient access to emergency medical professionals. Their responders visit patients at home to address physical, mental, and social health needs, utilizing technology to connect with advanced medical providers. Ready Responders also facilitates connections to external resources for ongoing support and aims to improve patient experiences while reducing overall care costs. The company operates in multiple locations across Louisiana, Nevada, New York City, and the National Capital Region, and is in-network with many major insurance providers.
RubiconMD, Inc. is a New York-based company that provides an online platform designed to facilitate communication between primary care clinicians and specialists through its eConsult service. This platform enables primary care providers to discuss cases with top specialists, thereby improving patient care and reducing costs. In addition to eConsults, RubiconMD offers a range of services, including a continuing medical education (CME) credit program, live and on-demand CME webinars, and RubiconRx, a clinical pharmacy platform that supports medication access for patients. The company also provides integration services for electronic health records, onboarding and implementation support, and clinician engagement. Founded in 2013, RubiconMD serves a diverse clientele that includes employers, community health centers, correctional health clinicians, health plans, health systems, and direct primary care practices.
Developer of a healthcare device designed to reduce sympathetic nerve activity and address the root cause of heart failure. The company's device allows clinicians to ablate the right greater splanchnic nerve using a small catheter inserted through the groin and helps to normalize sympathetic nervous activity, to shift blood volume from the heart back to the splanchnic bed, reducing pressures in the heart, enabling clinicians to begin treatment quickly, resulting in a higher likelihood of successful treatment.
Frontier Medicines Corporation is a pre-clinical stage biopharmaceutical company based in South San Francisco, California, founded in 2018. The company specializes in discovering and developing medicines that target cancer-causing proteins through its innovative chemoproteomics platform. This platform utilizes advanced computational techniques and machine learning to identify new binding pockets on proteins, thereby facilitating the discovery and development of small-molecule drugs. By enhancing the drug development process, Frontier Medicines aims to deliver breakthrough therapies that can significantly change the treatment landscape for debilitating diseases.
TriNetX, Inc. is a global health research network that facilitates collaboration among healthcare organizations, biopharmaceutical companies, and contract research organizations. The company provides a platform that enables researchers to analyze patient populations and derive real-world evidence, thereby enhancing trial design and improving site selection. Key offerings include TriNetX Live, a cloud-based solution for real-time analytics; TriNetX Research, which delivers longitudinal clinical data; and TriNetX Download, a platform for accessing real-world clinical data. Additionally, TriNetX features Attract Trials for data alignment in collaboration, Natural Language Processing for extracting clinical insights from physician documentation, and specialized tools for oncology research. Established in 2013 and headquartered in Cambridge, Massachusetts, TriNetX also has offices in Sydney, London, and Sao Paulo, and maintains compliance with HIPAA and GDPR regulations.
CathWorks Ltd. is a medical technology company based in Kfar-Saba, Israel, with an additional office in the United States. Founded in 2013, CathWorks specializes in developing advanced medical devices for the interventional cardiology market. The company's innovative technology leverages computational science and automatic multi-layered algorithms to enhance the utility of coronary angiography data, transforming visual assessments into objective decision-making tools for physicians. Its flagship product, CathWorks FFRangio, is a non-invasive device that provides objective multi-vessel physiological measurements, aimed at optimizing and confirming intra-procedural decisions for percutaneous coronary interventions (PCI). CathWorks is privately held and benefits from strong partnerships and support from leading venture capital firms in the medical devices sector.
SHINE Medical Technologies, LLC is a manufacturer and supplier of medical tracers and cancer treatment elements, specializing in isotopes used for diagnostic and therapeutic purposes. The company produces molybdenum-99, which is essential for imaging and diagnosing conditions such as cancer and heart disease. Additionally, SHINE offers Iodine-131 for the treatment of thyroid cancer and related conditions, as well as Iodine-125, which is utilized in brachytherapy for various cancers. The company also provides Xenon-133, an inhalable gas that assists in evaluating lung function and blood flow in the brain. Founded in 2010 and headquartered in Janesville, Wisconsin, SHINE serves both domestic and international markets with its innovative medical solutions.
Trinity Biotech is engaged in the development, manufacturing, and marketing of medical diagnostic products for clinical laboratories and point-of-care settings. The company offers a wide range of diagnostic tests and instrumentation that detect infectious diseases, sexually transmitted infections, autoimmune disorders, and conditions related to diabetes and liver health. With a portfolio of over 400 products, it employs various diagnostic formats, including immunofluorescence assays and enzyme-linked immunosorbent assays. Additionally, Trinity Biotech supplies raw materials to the life sciences and research sectors. Its products are marketed under several brand names, including Recombigen and Unigold, and are sold through a direct sales force and a network of independent distributors. The company serves a diverse clientele, including public health facilities, hospitals, and clinical laboratories. Founded in 1992 and headquartered in Bray, Ireland, Trinity Biotech has established a strong presence in the diagnostic market across regions including the Americas, Europe, Africa, and Asia.
Epic Sciences, Inc. is a diagnostics company based in San Diego, California, focused on improving cancer management through innovative testing methods. The company specializes in developing highly sensitive tests to identify and characterize circulating tumor cells (CTCs) from minimally invasive blood samples. Its advanced platform can profile single-cell phenotypes and genotypes, assessing various characteristics such as biomarker expression levels and morphologic traits. Epic Sciences also offers the Oncotype DX AR-V7 Nucleus Detect test for patients with metastatic castration-resistant prostate cancer, along with biopharmaceutical solutions. The company collaborates with biotechnology and pharmaceutical partners, major cancer centers, and research institutions, including the National Cancer Institute and the National Institutes of Health, to enhance personalized medicine and provide real-time biopsy material for cancer treatment guidance. Founded in 2008, Epic Sciences is committed to facilitating quick and effective cancer diagnostics.
Cureatr Inc. offers a mobile care coordination solution aimed at improving medication management for healthcare providers. By integrating HIPAA-secure text messaging with workflow navigation tools, Cureatr facilitates efficient communication among medical teams. The platform is accessible on Web, Android, and iPhone devices, ensuring real-time, universal access to accurate medication data for over 265 million patients. The company addresses the significant challenges of suboptimal medication management in the United States, which leads to substantial healthcare costs and mortality. With a focus on high-quality interventions provided by board-certified telepharmacists, Cureatr aims to enhance patient safety and reduce hospitalizations. Established in 2011, the company is headquartered in New York, New York.
Dracen Pharmaceuticals, Inc. is a biotechnology company based in Baltimore, Maryland, founded in 2016. The company specializes in the discovery and development of anticancer therapies, focusing on novel glutamine antagonists. These innovative therapies aim to directly reduce tumor size and improve the tumor microenvironment, thereby enhancing the effectiveness of immuno-oncology treatments. Dracen's approach seeks to increase the number of patients who respond to cancer therapies and extend survival rates, particularly in cases where traditional immuno-oncology methods have been less effective. Through its commitment to advancing cancer treatment, Dracen Pharmaceuticals is dedicated to improving outcomes for cancer patients.
Private Equity Round in 2018
ReMed is a brain injury rehabilitation company.
Quartet Health, Inc. is a healthcare technology company that operates a cloud-based platform designed to enhance communication and collaboration between medical and behavioral health providers. Founded in 2014 and based in New York, the company partners with health plans and health systems to deliver actionable insights and reports on behavioral health conditions, ultimately aiming to improve patient outcomes. Quartet's platform facilitates access to suitable mental health care tailored to individual preferences and clinical needs, ensuring that care is compatible with patients' insurance plans. By connecting physicians, mental health providers, and insurance companies, Quartet seeks to improve the overall health of patients while also reducing healthcare costs.
Fractyl Health Inc. is a medical device company specializing in innovative therapies for metabolic diseases, particularly type 2 diabetes and obesity. The company's flagship product, Revita DMR, is a minimally invasive procedure that utilizes hydrothermal ablation to rejuvenate the lining of the duodenum, effectively addressing the underlying causes of these conditions. By focusing on transforming the treatment of metabolic diseases from merely managing symptoms to providing durable, disease-modifying solutions, Fractyl Health aims to significantly improve patient health outcomes. Founded in 2010 and based in Lexington, Massachusetts, the company is committed to developing curative therapies that lessen the burden on patients, healthcare providers, and payers.
Melinta Therapeutics, Inc. is a commercial-stage pharmaceutical company specializing in the discovery, development, and commercialization of anti-infective therapies targeting bacterial infections. The company offers several products, including Baxdela, Vabomere, Orbactiv, and Minocin, which address various acute bacterial skin infections and gram-negative infections. Recognizing the urgent need for new antibiotics to combat drug-resistant infections, Melinta is advancing delafloxacin, currently in Phase 3 development for treating acute bacterial skin and skin structure infections. The company also focuses on developing innovative antibiotics aimed at overcoming resistant pathogens associated with serious hospital infections. Established in 2000, Melinta Therapeutics is headquartered in Morristown, New Jersey, and operates with support from strategic partners in the healthcare sector.
Adeptus Health is a healthcare organization focused on providing emergency medical care through a network of freestanding emergency rooms and strategic partnerships with various healthcare providers. The organization operates First Choice Emergency Room in Texas, a network of independent facilities equipped with advanced diagnostic radiology technology, including CT scans, ultrasounds, and digital X-rays, as well as on-site laboratories staffed by physicians and emergency-trained registered nurses. In Colorado, Adeptus collaborates with the University of Colorado Health to operate UCHealth Emergency Rooms. Additionally, in Arizona, the organization partners with Dignity Health to manage Dignity Health Arizona General Hospital and freestanding emergency rooms. In Louisiana, Adeptus has established a partnership with Ochsner Health System, further expanding its reach and accessibility in emergency medical care.
MIVI Neuroscience, Inc. is a medical device company based in Eden Prairie, Minnesota, specializing in clinical solutions for neurointerventional procedures. Founded in 2013, the company offers an innovative portfolio that includes products such as high flow tubing, various guide and diagnostic catheters, and aspiration pumps. MIVI's devices are designed to enhance patient outcomes by improving the safety and efficacy of treatments for ischemic stroke, facilitating the removal of obstructions and restoring blood flow. By focusing on reducing complications and procedure times, MIVI aims to expand treatment options for a broader range of patients, ultimately advancing the field of neurointervention.
Homology Medicines, Inc. is a genetic medicines company based in Bedford, Massachusetts, focused on improving the lives of patients with rare genetic diseases. The company employs a proprietary platform that utilizes human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs) to deliver genetic therapies in vivo, either through gene therapy or nuclease-free gene editing. This innovative approach allows for targeted treatment of various disease-relevant tissues, including the liver and central nervous system, through a single injection. Homology's lead product candidate, HMI-102, is currently in a Phase 1/2 clinical trial for treating phenylketonuria (PKU) in adults, while HMI-103 targets pediatric PKU patients, and HMI-202 is being developed for metachromatic leukodystrophy. Founded in 2015, Homology Medicines aims to address significant unmet medical needs by targeting the underlying causes of genetic disorders.
Aziyo is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. From our proprietary tissue processing platforms, we have developed a portfolio of advanced regenerative medical products that are designed to be very similar to natural biological material.
Synlogic, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of synthetic biotic medicines aimed at treating metabolic, inflammatory, and cancer-related diseases. The company’s lead therapeutic program, SYNB1618, is an oral therapy currently in Phase I/IIa clinical trials for the treatment of phenylketonuria. Additionally, Synlogic is developing SYNB1891, an intratumoral synthetic biotic medicine that is undergoing Phase I clinical trials for the treatment of solid tumors and lymphoma. The company is also exploring synthetic biotics for more common conditions, including inflammatory bowel disease and secondary hyperoxaluria. Synlogic has established a collaboration with Ginkgo Bioworks to advance its development of these innovative therapies.
Endologix, Inc. is a medical device company that specializes in the development and manufacturing of minimally invasive treatments for abdominal aortic aneurysms (AAA). The company's product portfolio includes several endovascular aneurysm repair (EVAR) systems, such as the AFX endovascular AAA system, which features a minimally invasive delivery mechanism, and the VELA Proximal Endograft, designed for specific aortic neck anatomies. Additionally, Endologix offers the Ovation abdominal stent graft system and the Nellix endovascular aneurysm sealing (EVAS) system, which effectively seals aneurysms while ensuring adequate blood flow to the legs. The company also provides extensions and accessories to customize and facilitate the delivery of its devices. Endologix markets its products through a direct sales force and a network of third-party distributors and agents. Established in 1992 and based in Irvine, California, Endologix has evolved from its original name, Radiance Medical Systems, Inc., to focus solely on addressing critical aortic-related health issues.
Shockwave Medical, Inc. is a medical device company that specializes in intravascular lithotripsy technology aimed at treating calcified plaque in patients with various cardiovascular diseases. The company has developed the Lithoplasty™ family of balloon dilatation catheters, which incorporate lithotripsy electrodes to enhance the compliance of rigid vascular and valvular lesions before low-pressure dilation. This approach minimizes injury to healthy tissue and addresses limitations associated with traditional revascularization technologies. Shockwave offers specific catheters for different applications, including M5 catheters for above-the-knee peripheral artery disease, C2 catheters for coronary artery disease, and S4 catheters for below-the-knee peripheral artery disease. The technology is designed to facilitate more effective angioplasty and improve stent delivery, as well as enhance native tissue preparation for trans-catheter aortic valve replacement. Founded in 2009 and headquartered in Santa Clara, California, Shockwave Medical serves interventional cardiologists, vascular surgeons, and interventional radiologists across the United States and internationally.
ConcertoCare provides healthcare services primarily to dual-eligible patients enrolled in Medicare and Medicaid, as well as those with complex medical needs. The company focuses on addressing critical vulnerabilities faced by these patients and health plans by offering personalized primary care, chronic condition management, and support for transitions between various care settings. Additionally, ConcertoCare delivers medical, social, and logistical assistance to enhance patient outcomes. Founded in 2004 and based in Aliso Viejo, California, the company operates care centers in locations including Renton, Washington, and several cities in Michigan. The name Concerto reflects its holistic approach to healthcare, emphasizing collaboration among patients, providers, and health plans to ensure coordinated care that respects the dignity and health of each individual.
Bridge Medicines LLC offers drug discovery services. It focuses on developing technologies in academic institutions from human proof-of-concept to clinical development. The company develops inhibitors of ENL-YEATS for the treatment of acute leukemias, such as acute myelogenous leukemia and a series of orally active small molecule inhibitors of activated factor XII for the treatment of hereditary angioedema and other inflammatory disorders. Bridge Medicines LLC was founded in 2016 and is based in New York, New York.
FogPharma is a healthcare company founded in 2015 and headquartered in Gloucester, Massachusetts. The firm is dedicated to the pharmaceutical sector, with a primary focus on developing innovative treatments for cancer. It operates with the support of a diverse group of private and institutional investors, fostering collaboration among its founders, employees, and advisors. FogPharma aims to create a new class of medicines designed to extend and enhance the lives of cancer patients. The company's commitment to its mission drives its efforts to pioneer effective solutions in cancer treatment.
Homology Medicines, Inc. is a genetic medicines company based in Bedford, Massachusetts, focused on improving the lives of patients with rare genetic diseases. The company employs a proprietary platform that utilizes human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs) to deliver genetic therapies in vivo, either through gene therapy or nuclease-free gene editing. This innovative approach allows for targeted treatment of various disease-relevant tissues, including the liver and central nervous system, through a single injection. Homology's lead product candidate, HMI-102, is currently in a Phase 1/2 clinical trial for treating phenylketonuria (PKU) in adults, while HMI-103 targets pediatric PKU patients, and HMI-202 is being developed for metachromatic leukodystrophy. Founded in 2015, Homology Medicines aims to address significant unmet medical needs by targeting the underlying causes of genetic disorders.
Lumeris is an accountable care delivery innovation company that provides operational support, technology, and consulting services to health systems, payers, and providers. The company focuses on enhancing clinical and financial outcomes through a value-based care managed services platform. By combining guidance, expertise, and advanced technology, Lumeris collaborates with healthcare organizations to design, build, and optimize accountable care models. Their solutions aim to improve quality, reduce costs associated with chronic diseases, and elevate patient and physician satisfaction. Through innovative risk management and performance-driven strategies, Lumeris enables healthcare providers to achieve better health outcomes and enhance overall patient experiences.
Acutus Medical, Inc. is an arrhythmia management company that specializes in developing medical technologies for diagnosing and treating complex cardiac arrhythmias. Founded in 2011 and based in Carlsbad, California, the company designs, manufactures, and markets a comprehensive range of tools for catheter-based ablation procedures. Its product offerings include advanced imaging and mapping systems, such as the AcQMap console and workstation, along with diagnostic catheters and therapeutic devices like ablation catheters and robotic navigation systems. Acutus Medical's innovative platform enables electrophysiologists to visualize the heart's activation patterns, facilitating more effective treatment of arrhythmias. The company collaborates with medical scientists and engineers in the U.S. and Europe to enhance its product development and provides solutions to hospitals and electrophysiologists globally.
Synlogic, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of synthetic biotic medicines aimed at treating metabolic, inflammatory, and cancer-related diseases. The company’s lead therapeutic program, SYNB1618, is an oral therapy currently in Phase I/IIa clinical trials for the treatment of phenylketonuria. Additionally, Synlogic is developing SYNB1891, an intratumoral synthetic biotic medicine that is undergoing Phase I clinical trials for the treatment of solid tumors and lymphoma. The company is also exploring synthetic biotics for more common conditions, including inflammatory bowel disease and secondary hyperoxaluria. Synlogic has established a collaboration with Ginkgo Bioworks to advance its development of these innovative therapies.
Advantia Health, LLC is a healthcare delivery company focused on providing comprehensive services to women and their families. Founded in 2014 and headquartered in Arlington, Virginia, Advantia Health offers a range of services including obstetrics, gynecology, primary care, and mental wellness, with additional locations in Virginia, Maryland, Illinois, and Missouri. The company emphasizes high-quality and efficient care through the use of technology and well-designed outpatient facilities. Advantia Health also provides telehealth services, allowing patients to connect with healthcare providers via a web and mobile application, ensuring timely access to the right care in the appropriate setting.
Fractyl Health Inc. is a medical device company specializing in innovative therapies for metabolic diseases, particularly type 2 diabetes and obesity. The company's flagship product, Revita DMR, is a minimally invasive procedure that utilizes hydrothermal ablation to rejuvenate the lining of the duodenum, effectively addressing the underlying causes of these conditions. By focusing on transforming the treatment of metabolic diseases from merely managing symptoms to providing durable, disease-modifying solutions, Fractyl Health aims to significantly improve patient health outcomes. Founded in 2010 and based in Lexington, Massachusetts, the company is committed to developing curative therapies that lessen the burden on patients, healthcare providers, and payers.
Cureatr Inc. offers a mobile care coordination solution aimed at improving medication management for healthcare providers. By integrating HIPAA-secure text messaging with workflow navigation tools, Cureatr facilitates efficient communication among medical teams. The platform is accessible on Web, Android, and iPhone devices, ensuring real-time, universal access to accurate medication data for over 265 million patients. The company addresses the significant challenges of suboptimal medication management in the United States, which leads to substantial healthcare costs and mortality. With a focus on high-quality interventions provided by board-certified telepharmacists, Cureatr aims to enhance patient safety and reduce hospitalizations. Established in 2011, the company is headquartered in New York, New York.
NeoChord, Inc. is a medical technology company that specializes in developing devices to address degenerative mitral valve disease (DMR), a condition that can lead to serious complications such as atrial fibrillation and congestive heart failure. The company's flagship product is the NeoChord Artificial Chordae Delivery System, a disposable device designed to repair damaged heart chordae through a small incision while the heart continues to beat. This innovative approach allows for mitral valve repair to be performed via a 2 to 3-inch incision between the ribs, significantly less invasive than traditional methods that require larger incisions and the use of heart-lung machines. Founded in 2007, NeoChord is headquartered in St. Louis Park, Minnesota.
Shockwave Medical, Inc. is a medical device company that specializes in intravascular lithotripsy technology aimed at treating calcified plaque in patients with various cardiovascular diseases. The company has developed the Lithoplasty™ family of balloon dilatation catheters, which incorporate lithotripsy electrodes to enhance the compliance of rigid vascular and valvular lesions before low-pressure dilation. This approach minimizes injury to healthy tissue and addresses limitations associated with traditional revascularization technologies. Shockwave offers specific catheters for different applications, including M5 catheters for above-the-knee peripheral artery disease, C2 catheters for coronary artery disease, and S4 catheters for below-the-knee peripheral artery disease. The technology is designed to facilitate more effective angioplasty and improve stent delivery, as well as enhance native tissue preparation for trans-catheter aortic valve replacement. Founded in 2009 and headquartered in Santa Clara, California, Shockwave Medical serves interventional cardiologists, vascular surgeons, and interventional radiologists across the United States and internationally.
Trinity Biotech is engaged in the development, manufacturing, and marketing of medical diagnostic products for clinical laboratories and point-of-care settings. The company offers a wide range of diagnostic tests and instrumentation that detect infectious diseases, sexually transmitted infections, autoimmune disorders, and conditions related to diabetes and liver health. With a portfolio of over 400 products, it employs various diagnostic formats, including immunofluorescence assays and enzyme-linked immunosorbent assays. Additionally, Trinity Biotech supplies raw materials to the life sciences and research sectors. Its products are marketed under several brand names, including Recombigen and Unigold, and are sold through a direct sales force and a network of independent distributors. The company serves a diverse clientele, including public health facilities, hospitals, and clinical laboratories. Founded in 1992 and headquartered in Bray, Ireland, Trinity Biotech has established a strong presence in the diagnostic market across regions including the Americas, Europe, Africa, and Asia.
DepoMed is a specialty pharmaceutical company that specializes in developing and commercializing products aimed at treating pain and conditions related to the central nervous system. Founded in 1995, the company has built a reputation for integrating innovative technology into its therapeutic offerings and successfully guiding these products through clinical approval. DepoMed's portfolio includes four FDA-approved medications: Gralise, which is used for managing postherpetic neuralgia; Cambia, an oral solution for the acute treatment of migraines in adults; Zipsor, liquid-filled capsules designed for mild to moderate acute pain relief; and Lazanda, a nasal spray for managing breakthrough pain in cancer patients. The company continues to focus on addressing unmet medical needs through its specialized product offerings.
ECPM is a medical device company focused on designing and commercializing a platform of products and services for gastrointestinal caregivers. The Company offers a range of products and services that span single-use devices and infection control products, pathology, and imaging systems. Its products are used in colonoscopy and procedures of the upper GI tract, including esophagogastroduodenoscopy (EGD).
The company is headquartered in Alpharetta, Georgia.
SteadyMed Ltd. is a medical-device company pursuing innovative devices for delivering injectable therapeutic drugs for pain relief, diabetes and other chronic conditions.
The company's products are pre-filled drug-infusion patches that will be sold in conjunction with a series of pharma and device companies. Specific applications of the device will be tailored in accordance with the requirements of the company's partners.
Breathe Technologies, Inc. develops and manufactures innovative medical technologies aimed at treating respiratory insufficiency diseases. Founded in 2005 and based in Irvine, California, the company specializes in non-invasive open ventilation systems designed for patients suffering from conditions such as interstitial lung diseases and neuromuscular disorders. Its lightweight mechanical ventilators are equipped with features that support continuous ventilation while promoting patient mobility, making them suitable for use in various healthcare settings, including intensive care units and pulmonary rehabilitation. Breathe Technologies operates as a subsidiary of Hill-Rom, Inc., focusing on enhancing respiratory care both in hospital environments and at home.
Conventus Orthopaedics provides a range of orthopedic and sports medicine services. The physicians specialize in orthopedic surgery, reconstructive surgery, spine surgery, joint replacement, sports medicine, physical therapy, and operative care of fractures, arthritis, strains, sprains, and sports-related injuries. Conventus was formed by a team of medical professionals with the sole purpose of creating less invasive ways to treat challenging periarticular fractures. By leveraging advanced nitinol technology, the Conventus team has developed a platform technology that provides robust fixation and creates reliable repairs. The company was incorporated in 2009 and is based in Maple Grove, Minnesota.
MedAvail operates as a technology-enabled pharmacy company that integrates automated pharmacy services within clinics and other healthcare settings using its proprietary technology. The company offers comprehensive services through its robotic dispensing platform, known as the MedAvail MedCenter, alongside home delivery options. Additionally, it runs SpotRx, a telehealth platform that facilitates remote pharmacist consultations through on-site dispensing kiosks, complemented by home delivery services. MedAvail is headquartered in Mississauga, Canada.
SHINE Medical Technologies, LLC is a manufacturer and supplier of medical tracers and cancer treatment elements, specializing in isotopes used for diagnostic and therapeutic purposes. The company produces molybdenum-99, which is essential for imaging and diagnosing conditions such as cancer and heart disease. Additionally, SHINE offers Iodine-131 for the treatment of thyroid cancer and related conditions, as well as Iodine-125, which is utilized in brachytherapy for various cancers. The company also provides Xenon-133, an inhalable gas that assists in evaluating lung function and blood flow in the brain. Founded in 2010 and headquartered in Janesville, Wisconsin, SHINE serves both domestic and international markets with its innovative medical solutions.
SHINE Medical Technologies, LLC is a manufacturer and supplier of medical tracers and cancer treatment elements, specializing in isotopes used for diagnostic and therapeutic purposes. The company produces molybdenum-99, which is essential for imaging and diagnosing conditions such as cancer and heart disease. Additionally, SHINE offers Iodine-131 for the treatment of thyroid cancer and related conditions, as well as Iodine-125, which is utilized in brachytherapy for various cancers. The company also provides Xenon-133, an inhalable gas that assists in evaluating lung function and blood flow in the brain. Founded in 2010 and headquartered in Janesville, Wisconsin, SHINE serves both domestic and international markets with its innovative medical solutions.
Epion Health, Inc. is a provider of mobile health applications and content, utilizing a cloud-based application and content management solution. Founded in 2011 and headquartered in Roseland, New Jersey, the company focuses on enhancing patient engagement by offering tools that allow patients to access health information on their smartphones and other mobile devices. This enables them to better understand their health and prepare for medical visits. Additionally, Epion Health provides physicians with access to essential health information and pre-loaded medical applications, including drug references and dosage calculators, which support improved patient care and communication within the healthcare continuum.
OMNIlife science, Inc. specializes in the design, manufacture, and distribution of orthopedic devices, focusing on joint replacement solutions. Founded in 1999 and headquartered in East Taunton, Massachusetts, the company offers a range of products, including orthopedic implants for knees and hips, as well as advanced robotic navigation technology known as OMNINAV, which enhances the precision of total knee surgeries tailored to individual patients. The company serves a diverse international market, including regions such as South Africa, Switzerland, Turkey, and several European countries, distributing its products through various distributors. OMNIlife science operates as a subsidiary of Orthopaedic Synergy, Inc.
Wellfount Corp. offers pharmacy services to nursing facilities. The company offers utilization and compliance reviews, multi dose, compliance packaging used for cycle and routine meds, proprietary SOPs and clinical programs, daily deliveries, intravenous therapy (IV), total parenteral nutrition (TPN), customized invoicing, EHR application integration, and medical records. It also offers medications and consulting services. Wellfount Corp. was founded in 2006 and is based in Indianapolis, Indiana.
IMRIS Inc. specializes in providing integrated image-guided therapy environments that enhance surgical and interventional procedures. The company's flagship product, the VISIUS Surgical Theatre, combines advanced imaging technologies such as magnetic resonance imaging, computed tomography, and fluoroscopy within multi-purpose surgical suites. This innovative approach allows for intra-operative imaging, enabling clinicians to access critical information in real-time during surgeries. IMRIS's products are marketed globally to hospitals that serve patients in neurosurgery, interventional neurovascular, and cardiovascular fields. The VISIUS Surgical Theatre is designed to meet the essential needs of patients, healthcare providers, and medical facilities, improving the overall efficacy of surgical interventions.
MannKind Corporation is a biopharmaceutical company specializing in the development and commercialization of inhaled therapeutic products aimed at treating diabetes and pulmonary arterial hypertension. The company's flagship product, Afrezza, is an inhaled insulin designed to enhance glycemic control in adults with diabetes. Additionally, MannKind has a collaboration with United Therapeutics Corporation to develop a dry powder formulation of treprostinil for pulmonary arterial hypertension. Founded in 1991 and headquartered in Westlake Village, California, MannKind continues to focus on innovative solutions for patients with chronic conditions.
MannKind Corporation is a biopharmaceutical company specializing in the development and commercialization of inhaled therapeutic products aimed at treating diabetes and pulmonary arterial hypertension. The company's flagship product, Afrezza, is an inhaled insulin designed to enhance glycemic control in adults with diabetes. Additionally, MannKind has a collaboration with United Therapeutics Corporation to develop a dry powder formulation of treprostinil for pulmonary arterial hypertension. Founded in 1991 and headquartered in Westlake Village, California, MannKind continues to focus on innovative solutions for patients with chronic conditions.
SERMO, Inc. provides a social network for doctors in the United States and internationally. It provides SERMO, a virtual doctors’ lounge, teaching university, and international medical conference all rolled into one that facilitates authentic discussions, online learning, and medical crowdsourcing. The company was founded in 2005 and is based in New York, New York with additional offices around the world. As of July 19, 2012, SERMO, Inc. operates as a subsidiary of WorldOne Interactive.
Mako Surgical is a medical device company that specializes in advanced robotic arm solutions and orthopedic implants for minimally invasive knee and hip procedures. The company is known for its flagship product, MAKOplasty, which provides a restorative surgical option for orthopedic surgeons to address early to mid-stage osteoarthritic conditions in patients. The core technology includes a robotic arm interactive orthopedic system that features a tactile robotic arm and an integrated bone cutting instrument, along with a visualization component that assists surgeons with pre-operative and intra-operative guidance. This innovative approach facilitates tissue-sparing bone removal and ensures precise implant insertion and alignment. Founded in 2004 and headquartered in Florida, Mako Surgical has gained recognition for its rapid growth and commitment to customer service in the medical technology sector.
iCAD, Inc. (iCAD) is a provider of image analysis and workflow solutions that enable radiologists and other healthcare professionals to serve patients by identifying pathologies and pinpointing cancer earlier. iCAD offers a range of high-performance, expandable Computer-Aided Detection (CAD) systems and workflow solutions for mammography (film-based, digital radiography (DR) and computed radiography (CR), Magnetic Resonance Imaging (MRI), and Computed Tomography (CT)). iCAD's solutions aid in the early detection of the prevalent cancers including breast, prostate and colon cancer. The Company's CAD systems include algorithm and other technology together with standard computer and display equipment. CAD systems for the film-based analog mammography market also include a radiographic film digitizer, either manufactured by the Company or others for the digitization of film-based medical images. !
NxStage Medical, Inc. is a medical technology company that specializes in developing, manufacturing, and marketing products for the treatment of end-stage renal disease (ESRD) and acute kidney failure. Its flagship product, the NxStage System One, is a portable hemodialysis system primarily used for home dialysis. The company also offers the PureFlow SL, an integrated unit for water purification and dialysate production, along with chronic cartridges that support flexible dialysis options at home. Additionally, NxStage provides a telehealth platform called Nx2me Connected Health for managing home hemodialysis treatments and patient data. In its product line, NxStage includes bloodlines, needles, and dialysis fluids, and it operates dialysis centers to deliver direct patient care. Founded in 1998 and based in Lawrence, Massachusetts, NxStage Medical operates as a subsidiary of Fresenius Medical Care Holdings, Inc.
MiddleBrook Pharmaceutical Corporation
Post in 2007
MiddleBrook Pharmaceutical Corporation is a pharmaceutical company focused on developing and commercializing pulsatile drug products that fulfill substantial unmet medical needs in the treatment of infectious disease.
Breathe Technologies, Inc. develops and manufactures innovative medical technologies aimed at treating respiratory insufficiency diseases. Founded in 2005 and based in Irvine, California, the company specializes in non-invasive open ventilation systems designed for patients suffering from conditions such as interstitial lung diseases and neuromuscular disorders. Its lightweight mechanical ventilators are equipped with features that support continuous ventilation while promoting patient mobility, making them suitable for use in various healthcare settings, including intensive care units and pulmonary rehabilitation. Breathe Technologies operates as a subsidiary of Hill-Rom, Inc., focusing on enhancing respiratory care both in hospital environments and at home.